Clinical trials: WHO Grade 3 Glioma
NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
This is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated…
- Conditions
- NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
- Trial name
- NCT07755397
- Testing
- JBI-778
- Where
- 6 sites in India
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics India Limited
Glioma
Proton vs. Photon Radiotherapy for Patients With WHO Grade 2-3 Glioma
Patients with grade 2 and 3 gliomas who received photon radiation therapy as part of their standard treatment are at risk of developing cognitive impairments, depending on the tumor's location and the size of the target volume.
- Trial name
- GliProPh (NCT07750457)
- Testing
- Proton therapy, Photon therapy
- Where
- 2 sites in Germany
- Volunteers
- 80 people
- Sponsor
- University Hospital, Essen
Glioblastoma, WHO Grade II Glioma
Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients With Grade II-IV Glioma
This phase II trial studies how well intensity-modulated stereotactic radiation therapy works in treating patients with grade II-IV glioma.
- Conditions
- Glioblastoma, WHO Grade II Glioma, WHO Grade III Glioma
- Trial name
- NCT03251027
- Testing
- Intensity-Modulated Radiation Therapy, Quality-of-Life
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Glioma : Oligodendroglioma or Astrocytoma
Safusidenib for Patients With Newly Diagnosed IDH1-mutant CNS WHO Grade 3 Oligodendroglioma and Astrocytoma - a Single Arm Phase II Study
The precise positioning of the emerging group of pharmacological inhibitors of mutant IDH enzymes remains to be refined by further studies and defined in national and international guidelines.
- Trial name
- SAFU-G3 (NCT07832123)
- Testing
- Safusidenib
- Where
- Switzerland
- Volunteers
- 20 people
- Sponsor
- University of Zurich
High Grade Glioma
Prospective Evaluation of T-cell Immune Status in Patients With Newly Diagnosed High Grade Gliomas
The primary goal of this study is evaluate T cell immune status and immune reconstitution and the association with specific cytokines in patients with newly diagnosed HGGs undergoing the standard RT/TMZ and adjuvant TMZ.
- Trial name
- NCT02041611
- Testing
- Blood collections
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
WHO Grade III Gliomas, WHO Grade IV Gliomas
Safety and Efficacy Study for DC Vaccine in Recurrent or Progressive High-grade Gliomas
This is a single-center, open-label, multi-dose phase I clinical trial evaluating the safety, tolerability, and preliminary efficacy of ZSNeo-DC1.1, a personalized dendritic cell injection, in subjects with recurrent or…
- Trial name
- NCT06253234
- Testing
- personalized dendritic cell injection ZSNeo-DC1.1
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Beijing Tiantan Hospital
Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
Expanded Access to ANG1005 for Individual Patients
This is an expanded access study with ANG1005 treatment for two individual patients from Protocol ANG1005-CLN-03 with WHO Grade III Anaplastic Astrocytoma and WHO Grade III Anaplastic Oligodendroglioma and one individual patient…
- Conditions
- Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Breast Cancer With Recurrent Brain Metastases, Leptomeningeal Carcinomatosis
- Trial name
- NCT02755987
- Testing
- ANG1005
- Where
- 2 sites in United States
- Sponsor
- Angiochem Inc
Glioma of Brain
Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse
Open label, non-randomized, mono-center Phase I/II study in subjects with IDH-wildtype WHO grade III / IV glioma at first relapse.
- Trial name
- GLIOMOON (NCT03779230)
- Testing
- L19TNF
- Where
- 3 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Philogen S.p.A.
Astrocytoma, Glioblastoma
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
CC-90010-GBM-001 is a multi-center, open-label study to assess the pharmacokinetics (PK), pharmacodynamics (PD) and CNS penetration of CC-90010 following short-term interval therapy (4 daily doses ) prior to surgery, in subjects…
- Trial name
- NCT04047303
- Testing
- CC-90010
- Where
- 4 sites in United States, Spain
- Volunteers
- 20 people
- Sponsor
- Celgene
Intracranial Neoplasm, Low Grade Glioma
Fluoroethyltyrosine for Evaluation of Intracranial Neoplasms
This phase II trial studies how well F-18 fluoroethyltyrosine (fluoroethyltyrosine) works in detecting tumors in participants with intracranial tumors that have come back.
- Conditions
- Intracranial Neoplasm, Low Grade Glioma, Recurrent Glioblastoma, Recurrent World Health Organization (WHO) Grade II Glioma
- Trial name
- UC-GlioFET (NCT04044937)
- Testing
- F-18 Fluoroethyltyrosine (FET), Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 143 people
- Sponsor
- Thomas Hope
Malignant Glioma, Glioblastoma Multiforme
Study Evaluating ABT-414 in Japanese Subjects With Malignant Glioma
This study seeks to evaluate the tolerability, pharmacokinetics (PK), efficacy, and safety of ABT-414 in Japanese participants with newly diagnosed and recurrent, World Health Organization (WHO) grade III or IV malignant glioma.
- Trial name
- NCT02590263
- Testing
- Whole Brain Radiation, Temozolomide, ABT-414
- Where
- 22 sites in Japan
- Volunteers
- 53 people
- Sponsor
- AbbVie
Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation
Proton Radiation Therapy for Gliomas
In this research study the investigators are looking at a type of radiation called proton radiation. Proton radiation has been shown to deliver virtually no radiation beyond the area of the tumor, sparing surrounding normal…
- Conditions
- Low Grade Glioma, WHO Grade 3 Glioma With IDH1 Mutation, WHO Grade 3 Glioma With 1p/19q Codeletion
- Trial name
- NCT01358058
- Testing
- Proton radiation
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Massachusetts General Hospital
Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified
Dabrafenib Combined With Trametinib After Radiation Therapy in Treating Patients With Newly-Diagnosed High-Grade Glioma
This phase II trial studies how well the combination of dabrafenib and trametinib works after radiation therapy in children and young adults with high grade glioma who have a genetic change called BRAF V600 mutation.
- Conditions
- Anaplastic Astrocytoma, Anaplastic Astrocytoma, Not Otherwise Specified, Anaplastic Ganglioglioma, Anaplastic Pleomorphic Xanthoastrocytoma
- Trial name
- NCT03919071
- Testing
- Biospecimen Collection, Dabrafenib Mesylate, Lumbar Puncture
- Where
- 131 sites in United States, Puerto Rico
- Volunteers
- 58 people
- Sponsor
- National Cancer Institute (NCI)
Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma
Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas
This phase I trial studies the side effects and best dose of carboxylesterase-expressing allogeneic neural stem cells when given together with irinotecan hydrochloride in treating patients with high-grade gliomas that have come…
- Conditions
- Recurrent Anaplastic Astrocytoma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Recurrent Glioblastoma
- Trial name
- NCT02192359
- Testing
- Carboxylesterase-expressing Allogeneic Neural Stem Cells, Irinotecan, Irinotecan Hydrochloride
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- City of Hope Medical Center
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Targeted Pediatric High-Grade Glioma Therapy
The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05839379
- Where
- 22 sites in United States, Australia and 5 more
- Volunteers
- 350 people
- Sponsor
- Nationwide Children's Hospital
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals